Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pridopidine for Levodopa-Induced Dyskinesia in Parkinson's Disease
NCT03922711Phase 2Terminated
- Sponsor
- Prilenia Therapeutics
- Start
- May 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pridopidine in levodopa-induced dyskinesia (LID) (3 arms), sponsored by Prilenia Therapeutics. Primary endpoint: Unified Dyskinesia Rating Scale at Week 16. Started May 2019; status: terminated.
02
Drugs
pridopidine
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT03922711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03922711.